Genmab Net Current Debt 2019-2025 | GMAB

Genmab net current debt for the twelve months ending March 31, 2025 was $-0.026B, a 22.34% decline year-over-year.

  • Genmab annual net current debt for 2024 was $-0.009B, a 34.16% decline from 2023.
  • Genmab annual net current debt for 2023 was $-0.013B, a 27.82% increase from 2022.
  • Genmab annual net current debt for 2022 was $-0.01B, a 12.02% increase from 2021.

Genmab Net Current Debt 2019-2025 | GMAB

  • Genmab annual net current debt for 2024 was $-0.009B, a 34.16% decline from 2023.
  • Genmab annual net current debt for 2023 was $-0.013B, a 27.82% increase from 2022.
  • Genmab annual net current debt for 2022 was $-0.01B, a 12.02% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$220.6B
Amgen (AMGN)$158.8B
Gilead Sciences (GILD)$136.4B
Vertex Pharmaceuticals (VRTX)$120.4B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$78.4B
CSL (CSLLY)$76.6B
Regeneron Pharmaceuticals (REGN)$61.3B
Alnylam Pharmaceuticals (ALNY)$41.1B
Argenex SE (ARGX)$34.2B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.2B
Biogen (BIIB)$19.7B
Insmed (INSM)$18.6B
Illumina (ILMN)$15.7B
Genmab (GNMSF)$14.2B
Incyte (INCY)$13.3B
Moderna (MRNA)$13B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Roivant Sciences (ROIV)$7.7B
Repligen (RGEN)$7.3B
Legend Biotech (LEGN)$7.2B